Tocilizumab
[대역어] 토실리주맙
[용어속성] Drug
[용어속성] Drug
Critically ill COVID-19 patients attended by anesthesiologists in northwestern Spain: a multicenter prospective observational study
Observational Study
[키워드] acute respiratory distress syndrome (ARDS)
Admission
Anesthesia
anesthesiologist
Anticoagulant
Anticoagulants
Antiviral
antiviral medication
Complication
complications
Corticoïdes
Corticosteroid
Corticosteroids
Course
COVID-19
COVID-19 patient
Critically ill
critically ill patients
Deceased
Decúbito prono
discharged
distress
evaluated
event
Final
Follow-up
High dose
hospital
ICU
Infection
information
intensive care
Intubated
mechanical ventilation
median
Mortality
multicenter
nine
outcome
outcomes
Pacientes críticos
pandemic
Patient
patients
prone
prone positioning
proportion
prospective observational study
required
SARS-CoV-2
Seven
Síndrome de distrés respiratorio agudo (SDRA).
Spain
syndrome
thrombosis
Thrombotic events
Tocilizumab
Treatment
was used
[DOI] 10.1016/j.redar.2020.08.004 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1016/j.redar.2020.08.004 PMC 바로가기 [Article Type] Observational Study
Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia
중증 SARS-CoV2 폐렴에서 토실리주맙의 동정적 사용
Article
[키워드] acute respiratory distress
acute respiratory distress syndrome
Administered
administration
age
analyzed
ARDS
benefit
C-reactive protein
compassionate-use
COVID-19
CRS
cytokine
Cytokine release syndrome
D-dimer
death
dose
drug
Evolution
Factor
FiO2
high oxygen support
High-sensitivity C-reactive protein
Hospitalized
hsCRP
IL-6
intensive care
interleukin-6
interleukin-6 receptor
intravenous
Intubated
intubation
Lymphocytes
male
Older age
oxygen
oxygen support
Patient
patients
Pneumonia
primary endpoint
Prognostic factors
receiving
receptor antagonist
required
respiratory distress
SARS-CoV-2
SARS-CoV-2 pneumonia
SARS-CoV2
saturation
severe disease
severe SARS
severe SARS-CoV-2
significantly
syndrome
TCZ
Tocilizumab
Treatment
[DOI] 10.1016/j.ijid.2020.10.045 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.ijid.2020.10.045 PMC 바로가기 [Article Type] Article
Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19
피하 토실리주맙을 사용한 인터루킨-6 수용체 차단은 COVID-19 환자의 응고 활성을 개선합니다
Article
[키워드] 95% confidence interval
95%CI
activate
activated
Admission
age
Analysis
Anticoagulants
blockade
Blood coagulation
C-reactive protein
change
Coagulation
Coagulation parameters
contribute
COVID-19
COVID-19 pathogenesis
COVID-19 patient
Critical
cytokine
D-dimer level
death
develop
dose
enrolled
evaluate the effect
fibrinogen
humanized monoclonal antibody
hypercoagulable
hyperinflammation
Hyperinflammatory
IMPROVE
increase in
Inflammation
interleukin-6
interleukin-6 receptor
interquartile range
laboratory-confirmed
moderate
occurred
Occurrence
parameter
Patient
patients with COVID-19
Platelet
Pneumonia
Prophylactic
Prophylaxis
Prothrombin time
receiving
receptor
reduction
reduction in
Respiratory function
Standard of care
Subcutaneous
subcutaneous dose
sustained
therapeutic
thromboembolic complications
Thromboprophylaxis
thrombosis
Tocilizumab
Treatment
were measured
[DOI] 10.1016/j.ejim.2020.10.020 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.ejim.2020.10.020 PMC 바로가기 [Article Type] Article
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
토실리주맙의 조기 치료와 COVID-19 중환자의 사망률 사이의 연관성
Article
[키워드] 30-Day mortality
95% CI
adjust
Admission
Analysis
baseline
Characteristics
cohort study
collected
coronavirus disease
COVID-19
Cox regression model
Critically ill patient
death
decrease
died
Follow-up
fraction
groups
hazard ratio
hospital
HRs
Hypoxemia
ICU
ICU admission
ICUs
Ill
IMPROVE
in-hospital mortality
include
Inflammatory cytokine
intensive care unit
interleukin 6 receptor
IQR
lower risk
male
mechanical ventilation
median
median age
monoclonal antibody
Mortality
multicenter cohort study
outcome
oxygen
Patient
patients treated
Prevalence
primary analysis
Probability
randomized clinical trial
receive
Research
risk
severe COVID-19 illness
survival
susceptible
syndrome
time
Tocilizumab
treated
Treatment
was used
Weighting
with COVID-19
[DOI] 10.1001/jamainternmed.2020.6252 PMC 바로가기 [Article Type] Article
[DOI] 10.1001/jamainternmed.2020.6252 PMC 바로가기 [Article Type] Article
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis
COVID-19 치료를 위한 약리학적 중재의 비교 효능 및 안전성: 체계적인 검토 및 네트워크 메타 분석
Meta-Analysis
[키워드] 1.26
95% CI
95% confidence interval
Admission
aggravation
Alpha
Anakinra
analyses
Analysis
anti-inflammatory agent
anti-inflammatory agents
Asia
assessment
associations
Azithromycin
benefit
Cardiac complications
cardiac safety risk
cardiac safety risks
cardiac-impaired population
cardiac-impaired populations
carried
categories
category
Causality
certainty
clinical
clinical benefit
clinical benefits
Clinical outcome
clinical settings
clinical trial
ClinicalTrials
clinician
Cochrane Library
collected
Combination
Comparative
controlled trials
convalescent plasma
coronavirus disease
Coronavirus disease 2019
Corticosteroid
Corticosteroids
Course
COVID-19
COVID-19 disease
COVID-19 disease course
COVID-19 treatments
CRD42020186527
Critically ill
Critically ill patient
critically ill patients
daclatasvir
dataset
determine
development
disease course
drug
effective
Efficacy and safety
eligibility criteria
eligible
Europe
evaluate
Evidence
evidence of
fatal cardiac complication
fatal cardiac complications
Google Scholar
help
heterogeneous
High-dose
Hospitalization
hospitalized COVID-19 patients
Hydroxychloroquine
ICU
Immunoglobulin
information
intensive care
intensive care unit
interferon
interferon-alpha
Intravenous immunoglobulin
investigated
itolizumab
Ivermectin
IVIG
Level
management
mechanical ventilation
medRxiv
Meta-analysis
Middle East
mild patients
moderate
moderate to severe
moderate/high evidence certainty
Mortality
mortality rate
mortality rates
Network meta-analysis
NMA
non-ICU
non-ICU setting
noncardiac serious adverse events
North America
Numerous
observational studies
observational study
Odds ratio
outcome
Patient
patients hospitalized
pharmacological agent
pharmacological intervention
pharmacological interventions
pharmacological management
plasma
Policy
populations
Potential treatment
potential treatments
progression
PROSPERO
provide
QT prolongation
QT prolongation incidence
Randomized controlled trial
Randomized controlled trials
randomized trial
randomized trials
RCT
RCTs
recommendations
reduce
reduce COVID-19 aggravation
reduce mortality rate
reduced
reflected
registry
Remdesivir
Research
researcher
Result
risk
risk of bia
RoB
RoB2
ROBINS-I framework
searched
self-limiting disease
Serious Adverse Event
Serious Adverse Events
severe COVID-19 patient
severe disease
severe pneumonia
shown
significantly
sofosbuvir
sofosbuvir plus daclatasvir
South America
SSRN
standard care
Study protocol
supported
systematic review
systematic synthesis
Tocilizumab
translated
Treatment
treatment regimen
viral clearance rate
vulnerable population
WHO
WHO International Clinical Trials Registry Platform
[DOI] 10.1371/journal.pmed.1003501 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1371/journal.pmed.1003501 PMC 바로가기 [Article Type] Meta-Analysis
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study
COVID-19 및 관련 폐렴 환자의 예후 인자 및 예후 인자: 후향적 코호트 연구
Virology
[키워드] ACE-inhibitors
adopted
Affect
Anticoagulant treatment
baseline
Brescia
Cancer
cardiovascular risk factor
cardiovascular risk factors
chronic obstructive
chronic obstructive pulmonary disease
clinical benefit
co-morbidity
consecutive patient
COVID-19
death
demonstrated
Dexamethasone
diabetes
died
discharge
disease
dose
drugs
enoxaparin
Factor
Follow-up
heart disease
Hospital admission
Hospitalization
Hydroxychloroquine
hypertension
in some
In-hospital
Italy
Lopinavir
morbidities
morbidity
obstructive pulmonary disease
once daily
outcome
patients
patients died
patients with COVID-19
Pneumonia
predictor
Prognosis
pulmonary disease
radiologic
Respiratory failure
retrospective cohort study
risk of death
Ritonavir
SARS-CoV-2
SARS-CoV2
survival
Tocilizumab
treated
Treatment
treatment with tocilizumab
variable
were assessed
worse prognosis
[DOI] 10.1042/BSR20203455 PMC 바로가기 [Article Type] Virology
[DOI] 10.1042/BSR20203455 PMC 바로가기 [Article Type] Virology
Effects of Tocilizumab in COVID-19 patients: a cohort study
COVID-19 환자에서 Tocilizumab의 효과: 코호트 연구
Observational Study
[키워드] Administered
black
Clinical improvement
cohort study
Complication
conducted
coronavirus
COVID-19
CRP
cytokine
Cytokine release syndrome
Cytokine storm
demonstrated
died
discharged
dose
early administration
early treatment
Effect
evaluated
help
Hispanic
hospital
Hospital admission
Hospitalized
Hyperinflammatory
Hyperinflammatory response
IL-6
IL-6 receptor
Infectious complications
initial
initial symptom
initial symptoms
intravenous tocilizumab
lack
male
median
median age
mitigate
Most patient
Most patients
observational study
occurred
PaO
Patient
progressive respiratory failure
randomized controlled study
receiving
reduction in
remained
Respiratory failure
Result
retrospective
SARS-CoV-2
slight increase
subsequent
supplementary material
sustained
Therapies
Tocilizumab
[DOI] 10.1186/s12879-020-05701-4 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1186/s12879-020-05701-4 PMC 바로가기 [Article Type] Observational Study
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
Pharmacology
[키워드] acute respiratory distress
acute respiratory syndrome
biologic agent
caused
Clinical outcome
colony stimulating factor
Comprehensive
coronavirus
Coronavirus disease 2019
COVID-19
COVID-19 patients
cytokine
death
detrimental
disease
disease modifying anti-rheumatic drug
DMARDs (biologic)
drug
Efficacy and safety
Evidence
hyper-inflammatory immune response
IL-6
immunesuppressants
IMPROVE
include
Inflammation
inflammatory condition
inhibiting
inhibitor
jak inhibitors
Janus kinase inhibitors
monoclonal antibody
Necrosis
observational study
patients
peak
pharmacological
randomized clinical trials
receptor
repurposing
review
sarilumab
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
syndrome
synthetic
therapeutic option
therapeutic strategy
tissue damage
Tocilizumab
Treatment
[DOI] 10.3389/fphar.2020.598308 PMC 바로가기 [Article Type] Pharmacology
[DOI] 10.3389/fphar.2020.598308 PMC 바로가기 [Article Type] Pharmacology
Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations
Article
[키워드] 95% confidence interval
adjusted hazard ratio
Admission
age
alanine aminotransferase
albumin level
ALT
analyzed
Aspartate aminotransferase
association
AST
baseline
correlated
Course
COVID-19
COVID-19 diagnosis
COVID-19 patients
death
diagnosis of COVID-19
Elevation
evaluate
evaluated
female
highest
hospital discharge
ICU
ICU admission
independent
information
intensive care
intensive care unit
interquartile range
Laboratory
liver enzyme
liver enzyme elevations
Male sex
median
Mortality
multifactorial
Patient
patients
patients with COVID-19
respiratory rate
risk
SARS-CoV-2
single-center
Steroids
Tocilizumab
Toxicity
transpeptidase
variable
while
with COVID-19
[DOI] 10.3390/microorganisms8122010 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/microorganisms8122010 PMC 바로가기 [Article Type] Article